CA3171219A1 - Compositions and methods for inducing immune responses - Google Patents

Compositions and methods for inducing immune responses Download PDF

Info

Publication number
CA3171219A1
CA3171219A1 CA3171219A CA3171219A CA3171219A1 CA 3171219 A1 CA3171219 A1 CA 3171219A1 CA 3171219 A CA3171219 A CA 3171219A CA 3171219 A CA3171219 A CA 3171219A CA 3171219 A1 CA3171219 A1 CA 3171219A1
Authority
CA
Canada
Prior art keywords
virus
nucleic acid
acid molecule
composition
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171219A
Other languages
English (en)
French (fr)
Inventor
Sean Michael Sullivan
Daiki MATSUDA
Kiyoshi Tachikawa
Padmanabh Chivukula
Priya Prakash Karmali
Jared Henry DAVIS
Yanjie Bao
Amit Sagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3171219A1 publication Critical patent/CA3171219A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1808—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3171219A 2020-03-09 2021-03-09 Compositions and methods for inducing immune responses Pending CA3171219A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062987191P 2020-03-09 2020-03-09
US62/987,191 2020-03-09
US202063073900P 2020-09-02 2020-09-02
US63/073,900 2020-09-02
PCT/US2021/021572 WO2021183563A1 (en) 2020-03-09 2021-03-09 Coronavirus vaccine compositions and methods

Publications (1)

Publication Number Publication Date
CA3171219A1 true CA3171219A1 (en) 2021-09-16

Family

ID=77671984

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3171219A Pending CA3171219A1 (en) 2020-03-09 2021-03-09 Compositions and methods for inducing immune responses
CA3171231A Pending CA3171231A1 (en) 2020-03-09 2021-03-09 Compositions and methods for inducing immune responses

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3171231A Pending CA3171231A1 (en) 2020-03-09 2021-03-09 Compositions and methods for inducing immune responses

Country Status (7)

Country Link
US (5) US11759515B2 (enExample)
EP (2) EP4117720A4 (enExample)
JP (2) JP2023517644A (enExample)
AU (2) AU2021233816A1 (enExample)
CA (2) CA3171219A1 (enExample)
TW (1) TW202200605A (enExample)
WO (2) WO2021183564A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426266A4 (en) * 2021-11-03 2025-11-05 Arcturus Therapeutics Inc LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT OF CYSTIC FIBROSIS

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526284B2 (en) * 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3171219A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
GB2605312B (en) 2020-03-23 2024-06-26 Hdt Bio Corp Compositions and methods for delivery of RNA
KR102813425B1 (ko) 2020-04-22 2025-05-28 바이오엔테크 에스이 코로나바이러스 백신
WO2022011332A2 (en) * 2020-07-10 2022-01-13 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
CA3191874A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
SE544840C2 (en) * 2020-09-28 2022-12-13 Stora Enso Oyj Method for the preparation of a bio-based carbon foam
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
TW202313967A (zh) * 2021-07-30 2023-04-01 美商亞克圖羅斯醫療公司 Ｒｎａ疫苗
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023044505A2 (en) * 2021-09-20 2023-03-23 Cyanvac Llc Piv5-based coronavirus vaccines and methods of use thereof
AU2022349251A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Sars-cov-2 rna vaccine compositions and methods of use
JP2024535351A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション 乾燥ナノ粒子組成物
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3234490A1 (en) * 2021-10-07 2023-04-13 Precision NanoSystems ULC Rna vaccine lipid nanoparticles
WO2023079472A2 (en) * 2021-11-03 2023-05-11 Kashiv Biosciences, Llc Multicistron expression vector for covid-19 vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US11510975B1 (en) * 2021-11-29 2022-11-29 Replicate Bioscience, Inc. Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
EP4440611A2 (en) * 2021-11-29 2024-10-09 Aegis Life, Inc. Sars cov-2 vaccine, associated polynucleotides, and methods of use
US20250041238A1 (en) * 2021-12-23 2025-02-06 Etherna Immunotherapies Nv METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs
KR20240130132A (ko) * 2022-01-05 2024-08-28 헬릭스 나노테크놀로지스 인코포레이티드 알파-인자 프리프로 서열을 포함하는 조성물 및 이의 용도
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
KR20240139971A (ko) * 2022-02-07 2024-09-24 세퀴러스 인코포레이티드 자가-복제 rna 및 이의 용도
CN116768987A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
AU2023256639A1 (en) * 2022-04-19 2024-10-31 Replicate Bioscience, Inc. Modified western equine encephalitis viruses and uses thereof
CN114557971B (zh) * 2022-04-25 2023-05-23 康希诺生物股份公司 一种核酸-脂质纳米颗粒的冷冻干燥保护剂及其制备方法和应用
US12084703B2 (en) 2022-05-12 2024-09-10 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator
WO2023221938A1 (zh) * 2022-05-16 2023-11-23 上海行深生物科技有限公司 蛋白包裹自复制rna及其制备方法
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2023230587A2 (en) * 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
US12186388B2 (en) * 2022-11-02 2025-01-07 Centre For Virology, Vaccinology And Therapeutics Limited Interferon-producing universal sarbecovirus vaccines, and uses thereof
WO2024163508A2 (en) * 2023-01-31 2024-08-08 Arcturus Therapeutics, Inc. Methods and compositions for quadrivalent influenza vaccine
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025104023A1 (en) * 2023-11-13 2025-05-22 Ziphius Nv MODIFIED ALPHAVIRAL nsP3
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025103414A1 (zh) * 2023-11-14 2025-05-22 上海瑞宏迪医药有限公司 一种脂质纳米粒的制备方法和应用
GB202400648D0 (en) * 2024-01-17 2024-02-28 Uea Enterprises Ltd Protein replacement therapy
WO2025189168A1 (en) * 2024-03-08 2025-09-12 SunVax mRNA Therapeutics Inc. Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy
JP7657411B1 (ja) * 2025-01-23 2025-04-07 医療法人すぎやま内科 乳がん細胞の増殖抑制剤及び乳がん治療剤

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437222T1 (de) 2001-09-06 2009-08-15 Alphavax Inc Alphavirus replikon-vektorsysteme
NZ542353A (en) 2003-03-20 2008-07-31 Alphavax Inc Improved alphavirus replicons and helper constructs
DK1751289T3 (da) 2004-05-18 2009-05-11 Alphavax Inc TC-83-afledte alfavirus-vektorer, partikler og fremgangsmåder
EP2811027A1 (en) * 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
AP2008004629A0 (en) 2006-02-27 2008-10-31 Univ Texas Pseudoinfectious flavivirus and uses thereof
JP2009544754A (ja) 2006-07-28 2009-12-17 アプライド バイオシステムズ， エルエルシー ジヌクレオチドｍｒｎａキャップアナログ
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
JP5602624B2 (ja) 2007-06-21 2014-10-08 アルファバックス， インコーポレイテッド αウイルス構造タンパク質の発現のためのプロモーターレスカセット
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
AU2008338803B2 (en) * 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
JP5749494B2 (ja) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
RU2010152562A (ru) * 2008-05-23 2012-06-27 Фит Байотек Ой (Fi) Векторы экспрессии, кодирующие репликазу альфавируса, и их применение в качестве иммунологического адьюванта
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
PL2355851T3 (pl) 2008-11-10 2018-08-31 Arbutus Biopharma Corporation Nowe lipidy i kompozycje do dostarczania środków terapeutycznych
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
US8883202B2 (en) 2009-05-05 2014-11-11 Tekmira Pharmaceuticals Corporation Lipid compositions
LT2440183T (lt) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Patobulinta lipido kompozicija
ES2647662T3 (es) 2009-12-31 2017-12-26 Medigen, Inc. Vacunas de ADN infeccioso frente al virus chikungunya
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
ES2586580T3 (es) * 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
SI2590676T1 (sl) 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virionu podobni delci za dajanje za samorepliciranje RNA molekul
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
WO2012030901A1 (en) 2010-08-31 2012-03-08 Novartis Ag Small liposomes for delivery of immunogen-encoding rna
SI3970742T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo RNA, ki kodira imunogen
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
SG10201605537XA (en) 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
WO2014170493A2 (en) 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
US10842859B2 (en) 2014-03-25 2020-11-24 Yale University Uses of parasite macrophage migration inhibitory factors
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US11559570B2 (en) * 2015-05-15 2023-01-24 CureVac SE Prime-boost regimens involving administration of at least one mRNA construct
EP4424835A3 (en) 2015-09-21 2024-10-23 TriLink BioTechnologies, LLC Compositions and methods for synthesizing 5'-capped rnas
WO2017083356A1 (en) * 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
CA3028721A1 (en) 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2018010815A1 (en) 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
CN110073002B (zh) 2016-10-17 2024-06-11 杨森制药公司 重组病毒复制子体系及其用途
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
US20200163878A1 (en) 2016-10-26 2020-05-28 Curevac Ag Lipid nanoparticle mrna vaccines
RU2019119272A (ru) 2016-11-23 2020-12-24 Гритстоун Онколоджи, Инк. Вирусная доставка неоантигенов
MX2019006467A (es) 2016-12-05 2019-12-09 Janssen Pharmaceuticals Inc Star Composiciones y métodos para mejorar la expresión génica.
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (en) * 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US20190374650A1 (en) 2017-02-22 2019-12-12 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer/biomacromolecule conjugates
WO2018160592A1 (en) 2017-02-28 2018-09-07 Arcturus Therapeutics, Inc. Translatable molecules and synthesis thereof
CN110612116A (zh) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 甲病毒新抗原载体
BR112019025224A2 (pt) * 2017-05-31 2020-12-08 Ultragenyx Pharmaceutical Inc. Terapêutica para doença de armazenamento de glicogênio tipo iii
EP3630985B1 (en) 2017-05-31 2025-08-27 Arcturus Therapeutics, Inc. Synthesis and structure of high potency rna therapeutics
IL272281B2 (en) * 2017-07-28 2023-04-01 Janssen Vaccines Prevention B V Methods and preparations for heterologous reprna vaccines
CN118976103A (zh) 2017-12-18 2024-11-19 英特维特国际股份有限公司 猪甲型流感病毒疫苗
EP3740245A4 (en) 2018-01-19 2022-01-05 Janssen Pharmaceuticals, Inc. INDUCTION AND ENHANCEMENT OF IMMUNE RESPONSES USING RECOMBINATION REPLICON SYSTEMS
WO2020014654A1 (en) 2018-07-13 2020-01-16 The Trustees Of Indiana University Recombinant rotavirus expression system and recombinant rotaviruses
EP3836963A2 (en) 2018-08-17 2021-06-23 GlaxoSmithKline Biologicals S.A. Immunogenic compositions and uses thereof
WO2020146700A1 (en) 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles
CA3133858A1 (en) 2019-03-19 2020-09-24 Arcturus Therapeutics, Inc. Method of making lipid-encapsulated rna nanoparticles
GB201908729D0 (en) 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
MA56535A (fr) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Co Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
EP4038194A1 (en) * 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CA3167611A1 (en) * 2020-02-13 2021-08-19 Etienne Simon-Loriere Nucleic acid vaccine against the sars-cov-2 coronavirus
EP4114470A4 (en) * 2020-03-03 2024-04-17 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
CA3171219A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
TW202313967A (zh) 2021-07-30 2023-04-01 美商亞克圖羅斯醫療公司 Ｒｎａ疫苗

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426266A4 (en) * 2021-11-03 2025-11-05 Arcturus Therapeutics Inc LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT OF CYSTIC FIBROSIS

Also Published As

Publication number Publication date
TW202200605A (zh) 2022-01-01
WO2021183564A1 (en) 2021-09-16
JP2023519173A (ja) 2023-05-10
CA3171231A1 (en) 2021-09-16
US11744887B2 (en) 2023-09-05
US11759515B2 (en) 2023-09-19
WO2021183563A1 (en) 2021-09-16
AU2021233816A1 (en) 2022-10-06
US20240115692A1 (en) 2024-04-11
US12220455B2 (en) 2025-02-11
AU2021236068A1 (en) 2022-10-06
EP4117720A4 (en) 2024-04-24
US20250161434A1 (en) 2025-05-22
US12390524B2 (en) 2025-08-19
EP4117720A1 (en) 2023-01-18
EP4117725A1 (en) 2023-01-18
EP4117725A4 (en) 2024-05-29
JP2023517644A (ja) 2023-04-26
US20240115691A1 (en) 2024-04-11
US20210290752A1 (en) 2021-09-23
US20210290756A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US12220455B2 (en) Coronavirus vaccine compositions and methods
US11241493B2 (en) Coronavirus vaccine
US11576966B2 (en) Coronavirus vaccine
US20230219996A1 (en) Rna vaccines
US20240181037A1 (en) Immunogenic compositions
US20240301007A1 (en) Methods and compositions for quadrivalent influenza vaccine